How AI Search Is Recommending Online Pharmacies: Monthly Trends

Executive Summary

Amazon Pharmacy remains the category leader, extending its coverage to 55.5% in October 2026 with its third consecutive month of significant gains. The gap to the next brand, CVS Pharmacy at 31.6%, widened to 23.9 points. Amazon Pharmacy's upward streak now spans three months and is the benchmark's clearest indicator of sustained movement at the top of the online pharmacy category.

Amazon Pharmacy was also the month's strongest upward mover, rising 9.9 points from September's 45.6% to October's 55.5%, and 18.1 points above its July baseline of 37.4%. Its rank-one recommendation rate climbed 17.1 points above baseline to 34.1%, and its top-three rate reached 46.9%. CVS Pharmacy followed as the second-largest riser, up 8.4 points from September to 31.6% and 11.2 points above its July baseline.

GoodRx and Optum Rx register as the period's sharpest decliners, both at 0.0% in October against July baselines of 26.1% and 10.6% respectively. These are not losses of AI recommendation favor: the benchmark split each brand into service-line entities, with GoodRx Care entering at 21.5% and Optum at 10.6% in the current month.

The category was active rather than stable. Eight brands registered as significant risers across the baseline-to-current span, two as significant decliners attributable to the tracking change, and two held stable. Amazon Pharmacy, CVS Pharmacy, and Walgreens each carried three-month upward streaks into October.

Each monthly run begins with 800 prompt-surface observations (555 unique questions in October) across the benchmark's defined AI/search surface universe. Of those, all 800 mentioned a tracked brand or competitor; 766 were relevant and 34 were irrelevant. The public metrics use the 642 observations in October and 641 in July that survive both qualification stages, with August contributing 596 qualified observations and September 643.

Key Findings

AI Response Inconsistency Alerts

The benchmark detected 3 critical/high factual inconsistencies across 4 AI platforms in the current month. These reflect conflicting claims produced by AI systems answering the same or similar pharmacy questions.

Amazon Pharmacy

A high-severity, high-confidence inconsistency concerned free delivery availability. When asked "How can I get my prescription delivered for free?", ChatGPT stated that Amazon Pharmacy offers free standard prescription delivery in all 50 states for eligible prescriptions, citing source pages including About Amazon's pharmacy explainer, Walgreens' mail service pharmacy page, and Capsule's site. Google AI Mode stated the opposite: that Amazon Pharmacy typically charges a small standard shipping fee rather than strictly free delivery, citing sources including Optum Rx's mail delivery page, CVS's delivery content, and RxOutreach. The benchmark flagged the About Amazon source page on the free-delivery side with high confidence, noting its claim that Amazon Pharmacy offers free prescription delivery to all 50 states. The two claims cannot both be true.

CVS Pharmacy

A high-severity, high-confidence inconsistency concerned the largest mail-order pharmacy ranking. When asked "Who is the largest mail order pharmacy?", ChatGPT stated that Express Scripts Pharmacy is the largest U.S. mail-order pharmacy, ahead of CVS Caremark, citing Becker's Hospital Review's PBM market-share coverage and Express Scripts' own FAQ page. Perplexity stated that CVS Health (CVS Caremark Mail) is the largest mail-order pharmacy in the U.S. by revenue, citing Becker's list of the 15 largest pharmacies in the U.S., Drug Channels' top 15 U.S. pharmacies analysis, and an Inven company list. The rankings are incompatible.

Express Scripts

A related high-severity, high-confidence inconsistency again concerned the largest mail-order pharmacy ranking. When asked "Who is the largest mail order pharmacy?", ChatGPT stated that Express Scripts Pharmacy is the largest U.S. mail-order pharmacy by prescription volume, citing the same Becker's PBM market-share page and Express Scripts FAQ. Gemini stated that CVS Health (CVS Caremark Mail Order) is the largest mail-order and specialty pharmacy network, citing Intuition Labs' specialty pharmacy guide and J.D. Power's 2025 U.S. Pharmacy Study. The two answers name different companies for the same title.

Benchmark Context

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

Benchmark-Level Metrics

These benchmark-level metrics summarize how the recommendation and shortlist mix moved across the two months, independent of any single brand.

The recommendation mix shifted sharply this period. September contributed 643 qualified observations, with a recommendation-shaped answer share of 28.9% and a valid recommendation shortlist share of 41.1%. From July to October, the valid recommendation shortlist share rose 22.4 points to 55.5%, meaning a clear majority of qualifying answers now take the form of structured shortlists rather than single named recommendations.

AI Recommendation Trend

Questions This Section Answers

• Who leads the online pharmacy category in AI recommendations, and how large is the gap to the next brand?
• Which pharmacy brands gained or lost recommendation coverage from July to October 2026?
• How did the GoodRx and Optum Rx entities change the top-ten ranking this month?

The Leader Is Widening Its Gap While the Field Consolidates Below It

Eight brands moved beyond normal month-to-month variation as significant risers across the baseline-to-current span, while GoodRx and Optum Rx registered as significant decliners reflecting the split into service-line entities rather than a loss of AI recommendation favor. Cost Plus Drugs and PillPack (Amazon Pharmacy) held stable. The category-level change came from the combination of Amazon Pharmacy's sustained climb, a broad-based second tier of gains, and the reclassification of two brands into their new entities.

What Changed This Month

Questions This Section Answers

• Which pharmacy brands registered as the month's largest risers and decliners?
• Why is Amazon Pharmacy's rank-one gain a stronger signal than its raw mention presence?
• What does the GoodRx and Optum Rx tracking change mean for the rest of the category?

Amazon Pharmacy: The Leader Extends a Three-Month Streak

Amazon Pharmacy gained 9.9 points of valid recommendation coverage, from 45.6% in September to 55.5% in October, and now sits 18.1 points above its July baseline of 37.4%. The gain is significant on both the baseline-to-current and prior-to-current comparisons, marking its third consecutive month of significant upward movement.

The brand's top-three recommendation rate rose 19.4 points above baseline to 46.9%, and its rank-one rate climbed 17.1 points to 34.1%, with 219 rank-one recommendations in October against 109 in July. Raw mention presence held essentially flat at 93.8% against the July baseline of 93.8%.

Amazon Pharmacy's recommendation quality is improving faster than its already-dominant presence. The brand is not merely mentioned in more answers; it is being named first far more often. The distinction matters because rank-one placement carries the default-choice weight in AI-driven pharmacy selection, and the gap between its presence and its rank-one rate is narrowing.

Highest-priority diagnostic: Which prompt categories are driving the rank-one gain, and how do rank-one placements compare across competing brands in those same categories?

CVS Pharmacy: Second Place with a Three-Month Streak

CVS Pharmacy gained 8.4 points from September to 31.6% in October, and 11.2 points above its July baseline of 20.4%. This marks its third consecutive month of upward movement, though the prior-to-current gain did clear the significance threshold.

Its top-three recommendation rate rose 12.5 points above baseline to 25.6%, while its rank-one rate edged up 1.6 points to 5.0%, with 32 rank-one recommendations in October against 22 in July. Raw mention presence eased 1.5 points from baseline to 79.0%.

CVS Pharmacy's coverage growth is outpacing its rank-one conversion. The brand is appearing in more recommendation shortlists without a proportional rise in first-place placements, which suggests its gains are concentrated in mid-list positions rather than top placement.

Highest-priority diagnostic: Why does CVS Pharmacy's rank-one rate trail its top-three rate by such a wide margin, and which prompts place it second or third rather than first?

Walgreens: Third Place with Broad Presence

Walgreens rose 4.1 points from September to 26.8% in October, and 8.1 points above its July baseline of 18.7%, carrying a three-month upward streak. Its top-three rate rose 6.7 points above baseline to 13.1%, and its rank-one rate edged up 0.6 points to 2.2%.

Raw mention presence declined 8.4 points from baseline to 72.9%, even as coverage rose. Net sentiment stands at 0.4, the lowest among the top three brands.

Walgreens is converting a smaller presence into more recommendation credit. Its coverage gain is real, but it comes alongside a shrinking mention footprint, which suggests the AI systems that do surface the brand are placing it higher in shortlists. The gap between its 72.9% presence and 26.8% coverage is the widest among the top three.

Highest-priority diagnostic: Which prompts recommend Walgreens mid-list but not first, and why is its sentiment score trailing the category leaders?

GoodRx and GoodRx Care: A Parent-to-Entity Repositioning

GoodRx moved to 0.0% coverage in October from 26.1% in July, registering as a significant decliner. GoodRx Care, tracked separately from September onward, stands at 21.5% in October, up 5.0 points from September and 21.5 points above its zero baseline, a significant riser.

GoodRx Care's raw mention presence is 30.8%, with a 12.3% top-three rate and a 4.5% rank-one rate. It holds 138 valid recommendations in October.

The parent brand's historical series is not directly comparable to the new entity's current coverage. The commercial question shifts from whether GoodRx is recommended to which of its service lines carries the recommendation weight. GoodRx Care's rank-one rate, at 4.5%, is now higher than CVS Pharmacy's, a placement pattern worth watching.

Highest-priority diagnostic: How do the parent brand's historical recommendation patterns distribute across its service-line entities, and which entity carries the rank-one placements?

Express Scripts: A Significant Riser on the Baseline Span

Express Scripts rose 5.2 points above its July baseline to 22.7% in October, clearing the significance threshold on the baseline-to-current comparison, though its 3.6-point prior-to-current gain did not. Its top-three rate rose 6.1 points to 13.7%, and its rank-one rate edged up 0.3 points to 1.9%.

Raw mention presence rose 4.0 points from baseline to 38.2%, with 146 valid recommendations in October. Net sentiment eased from 0.7 to 0.6.

Express Scripts' coverage gain is broad-based but shallow in placement terms. The brand is present in more answers and converting a modest share of that into top-three placements, but its rank-one rate remains low relative to the leaders.

Highest-priority diagnostic: Which prompts drove the coverage gain, and why does Express Scripts convert so little of its presence into rank-one placement?

Optum and Optum Rx: The Second Parent-to-Entity Move

Optum Rx moved to 0.0% coverage in October from 10.6% in July, registering as a significant decliner. Optum, tracked separately from September onward, stands at 10.6% in October, down 0.6 points from September but 10.6 points above its zero baseline, a significant riser on the baseline span.

Optum's raw mention presence is 24.4%, with a 4.0% top-three rate and a 0.5% rank-one rate. Net sentiment stands at 0.5, the lowest among the tracked brands.

The parent entity's historical series is not directly comparable to the new entity's current coverage. Optum's coverage is present but shallow, with a rank-one rate well below the category leaders and a sentiment score that trails the field.

Highest-priority diagnostic: Which service line carries Optum's recommendation weight, and why does its sentiment score trail the category?

Honeybee Health, Capsule, Cost Plus Drugs, and PillPack: Movement Within the Field

Honeybee Health rose 3.6 points above its July baseline to 13.7% in October, a significant riser on the baseline span, though its prior-to-current gain of 0.9 points did not clear the threshold. Its top-three rate rose 3.2 points to 6.2%, with a rank-one rate of 0.3% based on 2 rank-one recommendations, and 88 valid recommendations overall.

Capsule rose 4.5 points above baseline to 12.3% in October, a significant riser, driven by a 7.0-point prior-to-current gain. Its top-three rate rose 3.4 points to 8.1%, with 10 rank-one recommendations and 79 valid recommendations overall.

Cost Plus Drugs held stable at 19.8% in October, up 0.3 points from its July baseline of 19.5%, though its raw mention presence fell 8.8 points to 27.9% and its rank-one rate declined 2.2 points to 1.4%. It carries a two-month downward streak on the prior-to-current comparison.

PillPack (Amazon Pharmacy) held stable at 11.5% in October, up 2.1 points from its July baseline of 9.4%, with a 1.3-point prior-to-current decline. Its raw mention presence rose 4.3 points above baseline to 15.4%, with a rank-one rate of 2.0% and 74 valid recommendations overall.

This group shows expanding presence without proportional top-placement conversion. Capsule's significant rise is built on a single sharp month, while Cost Plus Drugs shows declining presence alongside flat coverage. For the smaller-count brands, the rank-one figures rest on single-digit recommendation counts, warranting additional scrutiny.

Highest-priority diagnostic: For each of these brands, which prompts drive the coverage movement, and why does rank-one placement lag so far behind presence?

Buyer-Intent Interpretation

Questions This Section Answers

• Which buyer-intent clusters drive AI pharmacy recommendations in the benchmark?
• Why can't the benchmark answer which pharmacy wins on price or in direct comparisons yet?

All 642 qualified observations in October fell into the Brand Recommendation cluster, continuing the pattern from July, August, and September where all qualified observations mapped to this cluster. The public benchmark surfaces no observations in the Pricing & Value or Multi-Brand Comparison clusters, meaning the commercial questions of which pharmacy wins on price and which wins in direct head-to-head comparison cannot yet be answered at the benchmark level. Those questions require company-level analysis into the prompts where pricing and comparison language appears, and the October response mix, which included 107 pricing-analysis and 25 comparison-analysis answers, suggests the underlying prompts exist even though they do not qualify into the public benchmark set.

Brand Opportunity Summary

Questions This Section Answers

• Which pharmacy brands show the strongest recommendation signal and which need diagnostic investigation?
• What are the highest-priority diagnostics for closing the gap between presence and rank-one placement?

The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations (query, surface, recommendation outcome, rank, sentiment, and citations where exposed). Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation, and the inconsistency alerts above illustrate why: when AI platforms cite different sources for the same question, the resulting claims can diverge even within a single month.

About This Benchmark

This report is part of the LLM Authority Index AI Visibility Market Discovery research program.

• AI Visibility Industry Market
• AI Visibility Industry Market Methodology
• AI Visibility Industry Market Metrics
• AI Visibility Industry Market Standards

Report-Specific Interpretation Notes

• Tracking change: GoodRx and Optum Rx moved to 0.0% in the current month because the benchmark began tracking GoodRx Care and Optum as separate entities; these are instrument changes, not losses of AI recommendation favor.
• Small-count movements: Honeybee Health's rank-one rate of 0.3% rests on 2 recommendations, and Capsule's 4.5-point baseline gain is built on a single sharp prior-to-current month; percentage movements on smaller recommendation bases warrant additional scrutiny.
• Factual inconsistency: The benchmark detected 3 critical/high conflicts across 4 AI platforms this month, centered on free delivery availability and mail-order pharmacy rankings; these reflect divergent sources rather than benchmark error.
• Qualified denominator vs raw collection: Brand-level percentages use the 642 qualified observations in October, not the 800 raw prompt-surface observations.
• Directional analysis: Month-over-month movement identifies changes worth investigating; it does not by itself establish the cause of those changes.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

Beneath the aggregate percentages sit the questions that determine pharmacy market position in AI search: which high-intent prompts does each brand win, which competitor takes the recommendation when a brand loses, what attributes does AI associate with each option, and which external sources shape those answers. The benchmark shows that Amazon Pharmacy's lead is widening on a three-month streak, that a broad second tier is rising beneath it, and that the GoodRx and Optum families have reorganized into separate service-line entities, but not the prompt-level dynamics behind those moves.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. That analysis turns the benchmark's findings into actionable intelligence for competing in AI-driven pharmacy discovery.

Request an AI visibility audit